Ozempic maker defends high U.S. price: It’s 'helping' reduce the cost of obesity
The CEO of Novo Nordisk defended the high cost of Ozempic and Wegovy in the U.S., saying the blockbuster drugs are ultimately saving taxpayers money on obesity-related costs.
The CEO of Novo Nordisk defended the high cost of Ozempic and Wegovy in the U.S., saying the blockbuster drugs are ultimately saving taxpayers money on obesity-related costs.
What's Your Reaction?
.gif)